Ono Pharmaceutical Co., Ltd. CEO Net Worth

Last Updated Mar 10, 2025
CEO NameGyo Sagara
NationalityJapan
Net Worth Estimation$10 million

Gyo Sagara, CEO of Ono Pharmaceutical Co., Ltd., holds significant executive compensation and stock options, reflecting his leadership of a global pharmaceutical entity. His estimated net worth of around $10 million is primarily attributed to accumulated salaries, performance bonuses, and ownership of company shares.

Gyo Sagara's estimated net worth of $10,000,000 places him at the minimum of the CEO net worth range for the healthcare sector, which spans $10,000,000 to $90,000,000. This means his net worth is exactly 11.1% of the maximum in the given range.

Business Category: Healthcare

Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 90000000 USD


Gyo Sagara Performance in Ono Pharmaceutical Co., Ltd.

Gyo Sagara, CEO of Ono Pharmaceutical Co., Ltd., demonstrates strong leadership through strategic innovation and decisive market expansion. His decision-making prioritizes R&D investment and global alliances, driving significant drug approval milestones. Under his tenure, Ono has enhanced corporate performance, achieving robust revenue growth and strengthened competitive positioning in the pharmaceutical industry.


Latest News

Ono Pharmaceutical Co., Ltd. CEO Gyo Sagara Leads Global Expansion and Strategic Acquisitions

Ono Pharmaceutical, under CEO Gyo Sagara, is advancing its global presence through major acquisitions like Deciphera Pharmaceuticals and expanding its oncology pipeline, while also focusing on sustainability and innovation in drug discovery. The company continues to strengthen its international operations and research collaborations, positioning itself as a leading global specialty pharma.
Source: http://www.statnews.com/2024/04/29/ono-pharmaceutical-to-acquire-deciphera-pharma/



Disclaimer.
The information provided in this document is for general informational purposes only and is not guaranteed to be complete. While we strive to ensure the accuracy of the content, we cannot guarantee that the details mentioned are up-to-date or applicable to all scenarios. Topics about Ono Pharmaceutical Co., Ltd. are subject to change from time to time.

Comments

No comment yet